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EDITORIAL
The Use of Life Expectancy in Cancer Screening Guidelines
Moving with Caution from Model-Based Evidence to Evidence-Based Guidelines
A critical question in preventive medicine is at what age
screening for cancer should stop.1,2 Mandelblatt et al. inves-
tigated this important issue for the case of mammography
screening, using a Monte Carlo simulation model that includ-
ed life expectancy as marker of physiologic age.3 They evalu-
ated the cost-effectiveness of screening until age 70, until age
79, and with no upper age limit. Their simulations suggested
that, at a threshold of $60,000 per life-year saved, screening to
age 79 is cost-effective only if it is limited to women with life
expectancies in the top quartile. At a threshold of $80,000,
biennial mammography screening until age 79 has reasonable
costs, with the researchers suggesting that ‘‘it is cost-effective
to screen women with a life expectancy of 9.5 years. This value
can be expected for 75% of 79-year-olds, about 50% of 80-
year-olds, and 25% of 85-year-olds.’’3 As is common with this
type of stochastic modeling exercise, the results were some-
what sensitive to different assumptions and parameters in the
model. Nonetheless, across a series of sensitivity analyses,
Mandelblatt et al.3 found that life expectancy rather than
chronologic age is important in assessments of optimal screen-
ing strategies. That is, the benefits of screening depend more
on how long a woman has left to live than on her actual age.
The type of research conducted by Mandelblatt et al. is
critically important in helping to identify ways to control health
care costs through evidence-based medicine. Nonetheless, we
need to be cautious in how we translate this kind of ‘‘evidence’’
from a policy simulation into ‘‘evidence-based’’ clinical guide-
lines, because guidelines that hinge on life expectancy raise
important practical and ethical concerns.
First, it is currently impractical to ask clinicians to base
screening decisions on life expectancy. Mandelblatt et al. ac-
knowledge this issue, stating that ‘‘one practical implication of
our analysis is that simple methods to determine life expect-
ancy in clinical settings could aid screening decisions for older
women.’’3 However, how close are we to having such methods?
While clinicians are relatively good at predicting survival
among terminally ill cancer patients, they tend to overestimate
length of life, even in the face of extensive data regarding out-
comes for these patients.4 In predicting life expectancy for
healthier patients, the current tools available are quite crude
and are of questionable validity. For example, Roizen has used
the popular press to promote his test for determining ‘‘real
age,’’ yet there is no scientific foundation for his approach.5
Welch et al.6 described a method for transforming chronologic
age into physiologic age, but their approach is quite simplistic,
relying on a single question regarding self-reported health sta-
tus. Significant investments have been made in gathering and
analyzing data from longitudinal population-based studies of
older cohorts (such as the Health and Retirement Study) to
better understand life expectancy among the elderly and the
predictors of successful aging.7,8 Such research, however, has
yet to be translated into validated tools that can be used in
clinical practice and public discourse. Thus, how do clinicians
know a woman in the top quartile of the life expectancy distri-
bution when they see one? Similarly, there is a 50-50 chance
that the 80-year-old woman in the office has 10 more years of
life ahead of her. How can a woman and her clinician know for
sure?
Second, mammography guidelines based on life expect-
ancy could further complicate physician-patient communica-
tion and reduce screening rates. Clinician recommendation is
a key predictor of women’s use of mammography.9,10 If breast
cancer screening guidelines were revised based on Man-
delblatt et al.’s results, clinicians would need to engage pa-
tients in relatively lengthy and difficult discussions regarding
projected life expectancy before making a recommendation. It
seems likely, however, that many physicians would simply re-
frain from discussing mammography and the unwieldy guide-
lines with a significant portion of their patients. Because
clinician recommendation is so important in mammography
use, forgoing these discussions would likely result in de-
creased screening rates among older women in general. This
could have negative consequences, as the incidence of breast
cancer rises with age, with risk peaking between the ages 65 to
74 for white women and 75 to 79 for African-American wom-
en.11 Mortality risk also rises steeply with age, with risk high-
est in the oldest age group. In fact, the age-adjusted breast
cancer mortality rate for those 85 and older is 197.1 per
100,000 for white women and 209.6 for African-American
women, more than double the rate for women ages 60 to 64
years.11 A clear guideline that is easy for physicians to inter-
pret, discuss, and implement with women is essential for op-
timal screening rates in older age groups.
Third, prognosis-based screening guidelines for older
adults also raise ethical concerns about how such policies
might reinforce social disparities in health. Publicly available
life tables provide information for the general population by
gender and major racial groups. It is clear, however, that there
is great heterogeneity within these groups, and that life ex-
pectancy also varies by education, income, ethnicity, and oth-
er markers of socioeconomic status (SES) and life
experience.8,12,13 Life expectancy is also affected by comor-
bidities and health risk behaviors, many of which are more
prevalent in lower SES and ethnic minority subpopulations.14
For example, the projected life expectancy of an African-Amer-
ican woman over age 75 with less than a high school education
and diabetes is not in the upper 25% of the distribution. As
such, social inequalities in health across the life course will be
reflected and reinforced in any screening guideline or policy
that uses life expectancy in its criteria. This can be considered
as a type of ‘‘statistical discrimination.’’15
In summary, a number of practical and ethical issues col-
lide when considering Mandelblatt et al.’s results in the con-
text of clinical guidelines for mammography screening.
Although these researchers were not issuing screening guide-
lines or recommendations themselves, their work could be in-
terpreted by some as providing an empiric basis for revised
mammography guidelines, especially in regard to the thorny
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yet important question of when to stop screening. This is not a
far-fetched concern, as screening guidelines that include as-
sessments of life expectancy already exist. For example, both
the American Cancer Society and the American Urological As-
sociation recommend prostate specific antigen screening for
those men who have ‘‘at least 10 years of life expectancy.’’16,17
Christakis18 claims that ‘‘prognostication is an essential
part of medicine.’’ He has also emphasized that predicting life
expectancy is a challenging endeavor, fraught with difficulty
and discomfort for patients and physicians alike.18,19 Christ-
akis’ work primarily focuses on end-of-life care, but his clarion
call for the development of better prognostic tools and aides
can be echoed here in the context of screening guidelines. Of
course, it is frustrating that most organizations issuing ma-
mmography guidelines have not included explicit recommen-
dations for women older than 70 years of age.20 As such, the
guidelines are murky at ages at which women are at very high
risk for being diagnosed with and dying from breast cancer.
Nonetheless, until we have better tools for understanding and
predicting life expectancy in different social groups, it would be
better to remain uncertain about when to stop screening
among older women than to open a Pandora’s box of practical
and ethical challenges. We therefore recommend that the re-
cent work by Mandelblatt et al. be used, not as ‘‘evidence’’ for
revising clinical guidelines for mammography screening, but
as a springboard for further discourse and debate about can-
cer screening in older age groups and as fuel for the develop-
ment of practical and valid prognostic tools for life
expectancy.—Paula M. Lantz, PhD,1 and Peter A. Ubel,
MD,2 1Department of Health Management and Policy, School
of Public Health and the Institute for Social Research, University
of Michigan, Ann Arbor, Mich; and 2Division of General Internal
Medicine, Center for Behavioral and Decision Sciences in Med-
icine, University of Michigan School of Medicine Ann Arbor Vet-
erans Affairs Medical Center, Ann Arbor, Mich.
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